
Modified GRF(1-29) — short-acting GHRH that preserves the natural pulsatile rhythm of growth hormone.
Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.
Ranges cited in research literature. Not a usage recommendation. For research use only.
CJC-1295 without DAC, technically named Modified GRF (1-29) or tetrasubstituted GRF(1-29), is an analog of the first 29 amino acids of human GHRH — the portion sufficient to activate its receptor — with four changes from the native sequence: D-alanine at position 2 (resists DPP-4), glutamine at 8 (prevents deamidation), alanine at 15 (improves affinity) and leucine at 27 (replaces an oxidizable methionine). It is the same sequence as CJC-1295 with DAC, minus the albumin-binding complex.
Without that complex its half-life is about 30 minutes: long enough to trigger a broad, clean GH pulse through the pituitary GHRH receptor, and short enough for secretion to return to its baseline pattern afterward. In research it is valued precisely for that: it allows studying the somatotroph response pulse by pulse, and combined with a ghrelin-receptor agonist it reproduces the GHRH + GHRP synergy described in humans.
There are no clinical efficacy trials of Mod GRF 1-29 as such; human data correspond to the pharmacology of GHRH analogs in general and to single-dose studies. It shares the whole class's considerations on GH and IGF-1 (glucose, fluid retention, theoretical caution in tumors) and appears on the World Anti-Doping Agency list. Renova distributes it for research only, individually and as a component of the blend with ipamorelin.
| Class | Short-acting GHRH(1-29) analog (Modified GRF 1-29) |
| Sequence | GHRH(1-29)-NH2 with D-Ala2, Gln8, Ala15, Leu27 (29 aa) |
| Substitutions | D-Ala2: DPP-4 resistance · Gln8: prevents deamidation · Ala15: affinity · Leu27: prevents oxidation |
| Receptor | GHRH receptor (anterior pituitary) |
| Half-life | ≈ 30 minutes |
| Difference from DAC | Same sequence without the albumin-binding group; short pulses instead of a days-long elevation |
| Regulatory status | Not approved; WADA list (S2) |
| Renova presentations | 5 mg vial; component of the CJC-1295 / Ipamorelin blend |
Because four substitutions were made on the first 29 amino acids of natural GHRH to make it more stable: a D-alanine that blocks the DPP-4 enzyme, a glutamine that prevents deamidation, an alanine that improves receptor binding and a leucine that replaces an oxidation-prone methionine. The active sequence is the same; the molecule lasts longer.
Both are GHRH(1-29). Sermorelin has the native sequence and a half-life of 10–20 minutes; Mod GRF 1-29 carries the four substitutions and lasts about 30 minutes. Sermorelin was approved as a medicine (Geref); Mod GRF 1-29 was never developed clinically.
They are different tools. Without DAC it produces short GH pulses resembling the physiological pattern; with DAC it raises GH and IGF-1 continuously for almost a week. The choice depends on what is being studied; our CJC-1295 + Ipamorelin stack guide explains both cases.
With ipamorelin, a selective ghrelin-receptor agonist, because the two classes potentiate each other in GH release. Renova offers that combination already co-lyophilized (CJC-1295 / Ipamorelin) or the separate vials to adjust the ratio.
Related reading: CJC-1295 + Ipamorelin: The Most-Studied GH Stack
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty